Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes

Record History

1. Minor Dec 15, 2025 2 versions Re-verified since Jun 3, 2012, no change to tracked fieldsv6-v7
2. Notable Aug 25, 2011 Primary endpoints revised (4) Secondary endpoint revisedv5 Show 1 more changeShow less

   • Secondary endpoint revised

   See this version in full on ClinicalTrials.gov ↗

3. Notable Jul 15, 2011 Results first posted: Aug 11, 2011 Primary endpoints: 1 to 4 · Secondary endpoints: 2 to 1v4 Show 2 more changesShow less

   • Primary endpoints: 1 to 4
   • Secondary endpoints: 2 to 1

   See this version in full on ClinicalTrials.gov ↗

4. Minor Feb 16, 2010 Study Status, Referencesv3
5. Minor Dec 26, 2007 Trial status: Recruiting to Completed Enrollment target: estimated 160 to confirmed 183 · Study sites: 1 to 0 · Completion date: Sep 2007 · 3 morev2 Show 6 more changesShow less

   • Enrollment target: estimated 160 to confirmed 183
   • Study sites: 1 to 0
   • Completion date: Sep 2007
   • Interventions: MCI-196 (Colestimide(JAN), Colestilan(INN), CHOLEBINE®) (Drug) to MCI-196 (Drug), Placebo of MCI-196 Tablet (Drug)
   • Secondary endpoints: 1 to 2
   • Study arms: 0 to 2

   See this version in full on ClinicalTrials.gov ↗

6. Minor Jul 5, 2007 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.